Ignite Creation Date:
2024-05-05 @ 11:26 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00049686
Status:
COMPLETED
Last Update Posted:
2013-07-18
First Post:
2002-11-12
Brief Title:
VNP40101M in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndrome
Sponsor:
Vion Pharmaceuticals
Organization:
National Cancer Institute NCI
Conditions & Keywords Data
Conditions:
| Name |
|---|
| MyelodysplasticMyeloproliferative Neoplasms |
| Leukemia |
| Myelodysplastic Syndromes |
Keywords:
| Name | View |
|---|---|
| myelodysplasticmyeloproliferative neoplasm unclassifiable | View |
| acute undifferentiated leukemia | View |
| chronic myelomonocytic leukemia | View |
| previously treated myelodysplastic syndromes | View |
| prolymphocytic leukemia | View |
| recurrent adult acute lymphoblastic leukemia | View |
| recurrent adult acute myeloid leukemia | View |
| refractory chronic lymphocytic leukemia | View |
| refractory anemia with excess blasts | View |
| refractory cytopenia with multilineage dysplasia | View |
| refractory hairy cell leukemia | View |
| relapsing chronic myelogenous leukemia | View |
| secondary acute myeloid leukemia | View |
| secondary myelodysplastic syndromes | View |
| atypical chronic myeloid leukemia BCR-ABL1 negative | View |